Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM32XZT)

Drug Name
Trospium chloride Drug Info
Synonyms Regurin; Sanctura
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Approved [1]
Therapeutic Class
Respiratory Agents
Cross-matching ID
PubChem CID
5284631
ChEBI ID
CHEBI:32270
CAS Number
CAS 10405-02-4
TTD Drug ID
DM32XZT
VARIDT Drug ID
DR01284

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTP
DOT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [3]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [4]
Methotrexate DM2TEOL Anterior urethra cancer Approved [5]
Folic Acid DMEMBJC Colorectal carcinoma Approved [6]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [5]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [5]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [7]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [5]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [8]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Organic cation transporter 1 (SLC22A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [10]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [11]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [12]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [13]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [3]
Verapamil DMA7PEW Angina pectoris BA40 Approved [14]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [15]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [16]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [17]
Propranolol DM79NTF Angina pectoris BA40 Approved [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Organic anion transporting polypeptide 1A2 (SLCO1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [19]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [20]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [21]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [22]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [23]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [24]
Saquinavir DMG814N Human immunodeficiency virus infection 1C62 Approved [25]
Enalapril DMNFUZR Congestive heart failure BD10 Approved [26]
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [27]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [28]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier organic anion transporter family member 1A2 (SLCO1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Saquinavir DMG814N Human immunodeficiency virus infection 1C62 Approved [25]
Hydroxyurea DMOQVU9 Chronic myelogenous leukaemia 2A20.0 Approved [29]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [30]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [31]
Testosterone enanthate DMB6871 N. A. N. A. Approved [32]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [33]
Cholecalciferol DMGU74E Adult acute monocytic leukemia Approved [34]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [35]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [36]
DTI-015 DMXZRW0 Brain cancer 2A00 Approved [37]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier family 22 member 1 (SLC22A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Phenoxybenzamine DM8KSQH Malignant essential hypertension BA00 Approved [38]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [39]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [40]
Lamivudine DMI347A Chronic HBV infection 1E51.0Z Approved [41]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [42]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [43]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [44]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [45]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [42]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [46]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [47]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [48]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [49]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [50]
Cepharanthine DM9Y5JB N. A. N. A. Approved [51]
Itraconazole DMCR1MV Aspergillosis 1F20 Approved [52]
Clozapine DMFC71L Schizophrenia 6A20 Approved [53]
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [54]
Trifluoperazine DMKBYWI Anxiety Approved [55]
Olanzapine DMPFN6Y Bipolar depression Approved [53]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier family 22 member 2 (SLC22A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [39]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [56]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [56]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [57]
Lamivudine DMI347A Chronic HBV infection 1E51.0Z Approved [41]
Famotidine DMRL3AB Gastric ulcer DA60 Approved [57]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [42]
Phenoxybenzamine DM8KSQH Malignant essential hypertension BA00 Approved [38]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [58]
Indomethacin DMSC4A7 Bursitis Approved [42]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier organic anion transporter family member 1B3 (SLCO1B3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Warfarin DMJYCVW Atrial fibrillation BC81.3 Approved [59]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [60]
Hydroxyurea DMOQVU9 Chronic myelogenous leukaemia 2A20.0 Approved [29]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [61]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [62]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [63]
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [61]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [31]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [64]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [65]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier organic anion transporter family member 1B1 (SLCO1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Enalapril DMNFUZR Congestive heart failure BD10 Approved [66]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [67]
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [68]
Repaglinide DM5SXUV Diabetic complication 5A2Y Approved [69]
Methotrexate DM2TEOL Anterior urethra cancer Approved [70]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [71]
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [72]
Ursodeoxycholic acid DMCUT21 Cholelithiasis DC11 Approved [72]
Hydroxyurea DMOQVU9 Chronic myelogenous leukaemia 2A20.0 Approved [29]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [73]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [2]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [2]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Regulation of Drug Effects [2]
Solute carrier family 22 member 1 (SLC22A1) OT7817I4 S22A1_HUMAN Regulation of Drug Effects [2]
Solute carrier family 22 member 2 (SLC22A2) OTGFK1AL S22A2_HUMAN Gene/Protein Processing [2]
Solute carrier organic anion transporter family member 1A2 (SLCO1A2) OTO70C5O SO1A2_HUMAN Regulation of Drug Effects [2]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1) OTNEN8QK SO1B1_HUMAN Gene/Protein Processing [2]
Solute carrier organic anion transporter family member 1B3 (SLCO1B3) OTOM3BUH SO1B3_HUMAN Gene/Protein Processing [2]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
3 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
4 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
5 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
6 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
7 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
8 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
9 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
10 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
11 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
12 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
13 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
14 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
15 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
16 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
17 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
18 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
19 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
20 Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
21 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
22 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
23 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
24 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
25 Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
26 Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
27 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
28 Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
29 Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
30 Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
31 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
32 Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
33 From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
34 The SLCO1A2 gene, encoding human organic anion-transporting polypeptide 1A2, is transactivated by the vitamin D receptor. Mol Pharmacol. 2012 Jul;82(1):37-46. doi: 10.1124/mol.112.077909. Epub 2012 Apr 3.
35 UDCA and CDCA alleviate 17-ethinylestradiol-induced cholestasis through PKA-AMPK pathways in rats. Toxicol Appl Pharmacol. 2016 Nov 15;311:12-25. doi: 10.1016/j.taap.2016.10.011. Epub 2016 Oct 12.
36 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
37 Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
38 Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
39 Involvement of aryl hydrocarbon receptor in the cytotoxicity of corannulene and its derivatives. Toxicol Lett. 2020 Mar 15;321:114-121. doi: 10.1016/j.toxlet.2019.12.012. Epub 2019 Dec 9.
40 Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005 Dec;315(3):1288-97.
41 Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther. 2009 Apr;329(1):252-61. doi: 10.1124/jpet.108.146225. Epub 2009 Jan 13.
42 Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
43 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
44 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
45 The pregnane X receptor down-regulates organic cation transporter 1 (SLC22A1) in human hepatocytes by competing for ("squelching") SRC-1 coactivator. Br J Pharmacol. 2016 May;173(10):1703-15. doi: 10.1111/bph.13472. Epub 2016 Apr 8.
46 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
47 Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
48 Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
49 Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
50 Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
51 Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
52 Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
53 Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
54 Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
55 Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
56 Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem Toxicol. 2012 Jul;50(7):2289-93. doi: 10.1016/j.fct.2012.03.077. Epub 2012 Apr 16.
57 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
58 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
59 Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population. Sci Rep. 2017 Dec 12;7(1):17379. doi: 10.1038/s41598-017-17731-1.
60 Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol. 2008 May;73(5):1474-83.
61 Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
62 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
63 Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
64 Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. Int J Mol Sci. 2021 Oct 12;22(20):11005. doi: 10.3390/ijms222011005.
65 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
66 Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men. Clin Ther. 2011 May;33(5):655-63. doi: 10.1016/j.clinthera.2011.04.018.
67 Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
68 Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
69 Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005 Jun;77(6):468-78. doi: 10.1016/j.clpt.2005.01.018.
70 SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients. Toxicol Sci. 2014 Nov;142(1):196-209. doi: 10.1093/toxsci/kfu162. Epub 2014 Aug 14.
71 SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-99.
72 Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res. 2006 Jun;47(6):1196-202.
73 Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther Drug Monit. 2007 Oct;29(5):666-8. doi: 10.1097/FTD.0b013e3181357364.